Scarica l'app Stockscreener
10.43
1.14%
-0.12
Dopo l'orario di chiusura:
10.47
0.04
+0.38%
Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - sg.finance.yahoo.com
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data - MarketBeat
Dimensional Fund Advisors LP Acquires 135,178 Shares of Sagimet Biosciences Inc. $SGMT - MarketBeat
Sagimet Biosciences (SGMT) Institutional Ownership 2026 - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Cut to "Sell" at Wall Street Zen - MarketBeat
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
SGMT (NASDAQ: SGMT) executive plans 350,987-share stock sale under Form 144 - Stock Titan
Sagimet Biosciences Inc. Series A Common Stock (NASDAQ: SGMT) Stock Price, News & Analysis - Kalkine
Sagimet Biosciences (NASDAQ:SGMT) Given New $29.00 Price Target at Citizens Jmp - MarketBeat
Citizens raises Sagimet stock price target to $29 on acne drug - Investing.com South Africa
Sagimet Biosciences (SGMT): Balyasny group discloses 5.93% ownership in Schedule 13G - Stock Titan
FDA Approves Sagimet Biosciences' IND for Phase 3 Denifanstat Acne Study - Kalkine Media
Sagimet Biosciences Receives US FDA Clearance for Phase 3 Acne Trial - marketscreener.com
Sagimet Biosciences Inc. (SGMT) Stock Price, News, Quote & History - ca.finance.yahoo.com
Form 8K Sagimet Biosciences Inc For: 13 August By Investing.com - Investing.com Nigeria
Sagimet gets FDA OK for late-stage acne trial (SGMT:NASDAQ) - Seeking Alpha
FDA clears Sagimet’s phase 3 trial for acne treatment denifanstat By Investing.com - Investing.com South Africa
Q4 EPS Estimate for Sagimet Biosciences Decreased by Analyst - MarketBeat
FDA clears Sagimet’s phase 3 trial for acne treatment denifanstat - Investing.com
FDA clears Sagimet Biosciences to begin Phase 3 trial of denifanstat for acne - Investing.com
Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026 - TradingView
Sagimet Biosciences Announces FDA Clearance of IND for Phase 3 Denifanstat Acne Trial - Quiver Quantitative
Sagimet Plans Acne Trial With About 800 Patients, 450 Expected Adolescents - Stock Titan
Sagimet Biosciences director George Kemble sells $201,146 in shares By Investing.com - Investing.com Canada
Sagimet Biosciences director George Kemble sells $201,146 in shares - Investing.com
Sagimet Biosciences (NASDAQ:SGMT) Director Sells 20,206 Shares of Stock - MarketBeat
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Given New $56.00 Price Target at Canaccord Genuity Group - MarketBeat
Why is Sagimet Biosciences stock climbing today? By Investing.com - Investing.com Australia
Here's Why We're Not At All Concerned With Sagimet Biosciences' (NASDAQ:SGMT) Cash Burn Situation - simplywall.st
Why is Sagimet Biosciences stock climbing today? - Investing.com
Sagimet Biosciences (SGMT) insider plans 20,206-share stock sale after option exercise - Stock Titan
Sagimet Biosciences at Canaccord Genuity conference: acne pivot gains traction - Investing.com Nigeria
Sagimet Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Sagimet Making 'Good Progress' in Bringing Denifanstat to US Patients, Wedbush Securities Says - marketscreener.com
Sagimet Biosciences Q2 Results: EPS misses estimate, losses widen 18.75% YoY - scanx.trade
Sagimet Biosciences (NASDAQ:SGMT) Issues Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Sagimet Biosciences Announces Q2 2026 Financial Results and Updates Investor Presentation - Kalkine Media
Form 8K Sagimet Biosciences Inc For: 11 August By Investing.com - Investing.com Nigeria
Sagimet Reports $14 Million Q2 Net Loss and Phase 3 Acne Trial Plans - Quiver Quantitative
Sagimet Biosciences (SGMT) posts Q2 loss but funds acne pipeline through 2028 - Stock Titan
Sagimet Biosciences (SGMT) boosts cash to $257.6M with 2026 stock sale - Stock Titan
Sagimet Plans Phase 3 Trial for Potential Once-Daily Acne Treatment - Stock Titan
Sagimet Biosciences (SGMT) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Renaissance Technologies LLC Increases Stake in Sagimet Biosciences Inc. $SGMT - MarketBeat
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BlackRock, Inc. Expands Stake in Sagimet Biosciences Inc (SGMT) With Strategic Add - GuruFocus
Sagimet: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026 - Seeking Alpha
Sagimet Biosciences (SGMT) to Release Quarterly Earnings on Wednesday - MarketBeat
Exclusive BAC Article: Sagimet Biosciences; China NDA Acceptance Denifanstat For Acne, 2nd Half 2026 U.S. Study Initiation, MASH Drug Combination, And Catalysts (NASDAQ:SGMT) - Seeking Alpha
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):